Samsung Biologics, a contract development and manufacturing organization (CDMO), commenced GMP operations this month at its Plant 4, the world’s largest single biomanufacturing plant. Plant 4’s partial operations comes 23 months after construction began in November 2020, adding production capacity of 60,000 liters. Plant 4 will have a total capacity of 240,000 liters when it becomes fully completed in the first half of next year.   Plant 4 is expected to help the company ma...